NeuroPace (NPCE) Gains from Investment Securities (2020 - 2021)
NeuroPace's (NPCE) quarterly Gains from Investment Securities came in at $2.1 million in Q2 2021, down 32.74% quarter-over-quarter from $3.1 million in Q1 2021.
NeuroPace (NPCE) Gains from Investment Securities (2020 - 2021) Analysis & Trends
NeuroPace's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $2.1 million for Q2 2021.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $2.1 million in Q2 2021; TTM through Mar 2022 was $2.1 million, a 28.6% decrease from a year earlier, with the FY2021 full-year figure at $5.2 million, up 2992.82% from the prior year.
- Gains from Investment Securities eased to $2.1 million in Q2 2021 per NPCE's latest filing, from $3.1 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $3.1 million in Q1 2021 and bottomed at -$181000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.59 Bn | 176.29 Bn | 6.27 Bn |
| 2 | Stryker | 129.07 Bn | 126.19 Bn | 3.81 Bn |
| 3 | Medtronic | 108.58 Bn | 99.36 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.64 Bn | 67.19 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.38 Bn | 44.71 Bn | 1.29 Bn |
| 6 | Dexcom | 28.35 Bn | 27.23 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.13 Bn | 25.84 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.90 Bn | 26.33 Bn | - |
| 9 | Koninklijke Philips | 24.27 Bn | 21.15 Bn | 2.07 Bn |
| 10 | NeuroPace | 517.55 Mn | 463.57 Mn | 18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 2.10 Mn |
| Jun 30, 2021 | 2.10 Mn |
| Mar 31, 2021 | 3.12 Mn |
| Mar 31, 2021 | 3.12 Mn |
| Dec 31, 2020 | -181,000.00 |
| Dec 31, 2020 | -181,000.00 |